Home Physical Sciences Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-phenylprop-2-en-1-one, C14H14N2O2
Article Open Access

Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-phenylprop-2-en-1-one, C14H14N2O2

  • Radi Smaail EMAIL logo , Said Tighadouini , Driss Eddike , Monique Tillard and Yahia N. Mabkhot
Published/Copyright: December 17, 2016

Abstract

C14H14N2O2, orthorhombic, P212121 (no. 19), a = 5.6736(2) Å, b = 7.7803(4) Å, c = 28.7821(13) Å, V = 1270.5(1) Å3, Z = 4, Rgt(F) = 0.0454, wRref(F2) = 0.0879, T = 298 K.

CCDC no.:: 1485894

Source of material

Ethyl-1,5-dimethyl-1H-pyrazole-3-carboxylate (2.02 g; 12.01 mmol) was slowly added to a solution of metallic sodium (0.35 g; 15.21 mmol) in 50 mL of anhydrous toluene. Then, acetophenone (1.44 g; 12.01 mmol) in 10 mL of toluene was added at 0 °C. The resulting mixture was stirred at room temperature for 7 days. The precipitate formed was filtered, washed with toluene, dissolved in water and neutralized with acetic acid. The product extracted with CH2Cl2 was concentrated in vacuo and precipitated in hexane. Crystals of the title compound were obtained from hot ethanol by slow evaporation. Yield: 32%; M.p. 108–110 °C.

Table 1

Data collection and handling.

Crystal:Colourless plate
Size:0.40 × 0.15 × 0.07 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.9 cm−1
Diffractometer, scan mode:Xcalibur Sapphire3, ω-scans
2θmax, completeness:55.4°, >89% (99.4% up to 50.5°)
N(hkl)measured, N(hkl)unique, Rint:8426, 2596, 0.035
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 1646
N(param)refined:173
Programs:CrysAlis [11], SHELX [12], ORTEP [13]
Table 2

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
C10.4206(5)0.7032(4)0.15932(9)0.0458(8)
C20.6125(5)0.6156(4)0.14197(9)0.0476(8)
H20.68930.53600.16070.057*
C30.6944(5)0.6438(4)0.09665(9)0.0480(8)
C40.8970(4)0.5512(4)0.07777(9)0.0446(7)
C51.0080(5)0.5761(4)0.03494(9)0.0476(8)
H50.96690.65550.01220.057*
C61.1873(5)0.4616(4)0.03326(9)0.0479(8)
C71.3676(5)0.4268(5)−0.00323(9)0.0627(9)
H7A1.52190.44900.00910.094*
H7B1.33980.5002−0.02950.094*
H7C1.35720.3088−0.01280.094*
C81.3290(5)0.2316(5)0.08903(11)0.0763(11)
H8A1.46960.27760.10280.114*
H8B1.37040.16170.06280.114*
H8C1.24660.16300.11150.114*
C90.3333(4)0.6900(4)0.20725(9)0.0426(7)
C100.1240(5)0.7691(4)0.21946(10)0.0565(9)
H100.03430.82360.19680.068*
C110.0467(5)0.7681(5)0.26485(13)0.0671(10)
H11−0.09410.82220.27260.080*
C120.1768(6)0.6876(5)0.29873(11)0.0646(9)
H120.12540.68860.32940.078*
C130.3833(5)0.6055(4)0.28713(10)0.0606(9)
H130.47050.54920.30980.073*
C140.4608(5)0.6071(4)0.24151(10)0.0513(8)
H140.60070.55160.23380.062*
N11.1782(4)0.3720(3)0.07386(8)0.0519(6)
N21.0014(4)0.4251(3)0.10172(7)0.0538(7)
O10.3059(3)0.8116(3)0.13283(6)0.0647(6)
H10.39590.81690.10240.097*
O20.5935(3)0.7515(3)0.06995(7)0.0665(7)

Experimental details

All hydrogen atoms were inserted at calculated positions and refined using a riding model. The Uiso values of the hydrogen atoms of methyl groups were set to 1.5Ueq(C) and the Uiso values of all other hydrogen atoms were set to 1.2Ueq of their parent atoms.

Discussion

Many heterocycles branched β-keto-enol are useful synthetic intermediates in a wide variety of applications including anti-tumor [1, 2, 3], anti-inflammatory [4] and anti-HIV [5, 6] activities. Recently, we have reported some new heterocyclic keto-enol compounds that have shown remarkable biological activities [7] and efficient coordination properties [8, 9]. Herein, we report a β-keto-enol compound: (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-phenylprop-2-en-1-one, prepared in acceptable yield. The crystal structure shows the formation of an intramolecular (O1—H—O2) interaction balancing the intra-electrostatic forces. The two oxygen atoms O1, O2 are separated by a distance of 2.480(3) Å. Furthermore, the N1—N2 distance (1.349(3) Å) is in good agreement with the lengths of bonds reported for analogous compounds [10]. The N1, N2, C4, C5, and C6 atoms are in the same plane. The r.m.s. deviation is 0.002 Å. The torsion angle O2—C3—C4—N2 of -174.1(3) indicates that the pyrazole ring undergoes slight inclination with respect to the binding C3—C4. Also the phenyl atoms are in the same plane (0.005 Å), while the torsion angle O1—C1—C9—C14 of -167.6(3)° indicates that the plane of phenyl ring undergoes a inclination relative to plane of the rest of the molecule.

Acknowledgements

The authors extend their appreciation to the PPR2-MESRSFC-CNRST project (Morocco). Sincere appreciation was also extended to the Deanship of Scientific Research at King Saud University for its supporting this Prolific Research group (PRG-1437-29).

References

1 Goldgur, Y.; Craigir, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R.: Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. 96 (1999) 13040–13043.10.1073/pnas.96.23.13040Search in Google Scholar PubMed PubMed Central

2 Tan, K.L.; Ali, A.; Du, Y.; Fu, H.; Jin, H. X.; Chin, T. M.; Khan, M.; Go, M. L.: Synthesis and evaluation of bisbenzylidenedioxotetrahydro- thiopranones as activators of endoplasmic reticulum (ER) stress signaling pathways and apoptotic cell death in acute promyelocytic leukemic cells. J. Med. Chem. 57 (2014) 5904–5918.10.1021/jm401352aSearch in Google Scholar PubMed PubMed Central

3 Liang, G.; Shao, L.; Wang, Y.; Zhao, C.; Chu, Y.; Xiao, J.; Zhao, Y.; Li, X.; Yang, S.: Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg. Med. Chem. 17 (2009) 2623–2631.10.1016/j.bmc.2008.10.044Search in Google Scholar PubMed

4 Liang, G.; Li, X.; Chen, L.; Yang, S.; Wu, X.; Studer, E.; Gurley, E.; Hylemon, P. B.; Ye, F.; Li, Y.; Zhou, H.: Synthesis, anti-inflammatory activities of monocarbonyl analogues of curcumin. Bioorg. Med. Chem. Lett. 18 (2008) 1525–1529.10.1016/j.bmcl.2007.12.068Search in Google Scholar PubMed PubMed Central

5 Pommier, Y.; Johnson, A. A.; Marchand, C.: Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4 (2005) 236–248.10.1038/nrd1660Search in Google Scholar PubMed

6 Egbertson, S. S.; Anthony, N. J.; Summa, V.: HIV integrase inhibitors: from diketo acids to heterocyclic templates: history of HIV integrase medicinal chemistry at Merck West Point and Merck Rome (IRBM) leading to discovery of raltegravir. In: Pharmaceutical & Medicinal Chemistry, (Ed. Neamati, N.), pp. 197–230. John Wiley & Sons, Inc., Hoboken, NJ, USA 2011.10.1002/9781118015377.ch14Search in Google Scholar

7 Radi, S.; Tighadouini, S.; Feron, O.; Riant, O.; Bouakka, M.; Benabbes, R.; Mabkhot,Y.N.: Synthesis of novel β-keto-enol derivatives tethered pyrazole, pyridine and furan as new potential antifungal and anti-breast cancer agents. Molecules 20 (2015) 20186–20194.10.3390/molecules201119684Search in Google Scholar PubMed PubMed Central

8 Radi, S.; Tighadouini, S.; El Massaoudi, M.; Bacquet, M.; Degoutin, S.; Revel, B.; Mabkhot, Y.N.: Thermodynamics and kinetics of heavy metals adsorption on silica particles chemically modified by conjugated β-keto-enol furan. J. Chem. Eng. Data 60 (2015) 2915–2925.10.1021/acs.jced.5b00281Search in Google Scholar

9 Radi, S.; Tighadouini, S.; Bacquet, M.; Degoutin, S.; Revel, B.; Zaghrioui, M.: Quantitative removal of Zn(II) from aqueous solution and natural water using new silica-immobilized ketoenol-pyridine receptor. J. Env. Chem. Eng. 3 (2015) 1769–1778.10.1016/j.jece.2015.06.016Search in Google Scholar

10 Radi, S.; Tighadouini, S.; Ben Hadda, T.; Akkurt, M.; Özdemir, N.; Sirajuddin, M.; Mabkhot, Y.N.: Crystal structure of (2Z)-3-hydroxy-1-(1,5-dimethyl-1H-pyrazol-3-yl)but-2-en-1-one. Z. Kristallogr. NCS 231 (2016) 617–618.10.1515/ncrs-2015-0212Search in Google Scholar

11 Oxford Diffraction (2004). CrysAlis CCD and CrysAlis RED. Version 171. Oxford Diffraction Ltd, Abingdon, Oxfordshire, England.Search in Google Scholar

12 Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Search in Google Scholar PubMed

13 Farrugia, L. J.; WinGX, ORTEP for Windows, an update. J. Appl. Crystallogr. 45 (2012) 849–854.10.1107/S0021889812029111Search in Google Scholar

Received: 2016-7-17
Accepted: 2016-11-3
Published Online: 2016-12-17
Published in Print: 2017-3-1

©2016 Radi Smaail et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Articles in the same Issue

  1. Cover and Frontmatter
  2. The crystal structure of triphenylphosphineoxide – 2,5-dichloro-3,6-dihydroxycyclohexa-2,5-diene-1,4-dione (2/1), C42H32Cl2O6P2
  3. Crystal structure of poly-[diaqua-[bis(μ2-hydroxy)-bis(μ4-3,4,5,6-tetrachlorophthalato-κ3O,O′:O′; κ2O′′:O′′′)dilanthanum(III)], C8H3Cl4LaO6
  4. Crystal structure of 1,1′-(3,4-diphenylthieno[2,3-b]thiophene-2,5-diyl)bis[1-phenyl-methanone], C32H20O2S2
  5. Crystal structure of 4a-hydroxy-9-(3,5-dibromo-phenyl)-3,4,4a,5,6,7,9,9a-octahydro-2H-xanthene-1,8-dione, C19H18Br2O4
  6. Crystal structure of 5-hydroxy-4,6,9,10-tetramethyl-1-oxo-6-vinyldecahydro-3a,9-propanocyclopenta[8]annulen-8-yl 2-((2-methyl-1-(3-methylbenzamido)propan-2-yl)thio)acetate, C34H49NO5S
  7. Crystal structure of pyridinium bis(naphthalane-2,3-diolato-κ2O,O′)borate monohydrate, C25H20BNO5
  8. Crystal structure of 1,1′-((1E,1′E)-(((ethane-1,2-diylbis(oxy))bis(2,1-phenylene))bis(azanylylidene))bis(methanylylidene))bis(naphthalen-2-olato)nickel(II), C72H52N4O8Ni2
  9. The crystal structure of 3-(2-acetyl-4-butyramido-phenoxy)-2-hydroxy-N-isopropylpropan-1-aminium tetraphenylborate, C42H49BN2O4
  10. Crystal structure of 4-bromobenzyl (Z)-N′-(adamantan-1-yl)-4-phenylpiperazine-1-carbothioimidate, C28H34BrN3S
  11. Crystal structure of poly-[(μ6-benzene-1,2,4,5-tetracarboxylato)-(μ2-1,2-bis(imidazol-1-ylmethyl)benzene)dicobalt(II)], Co2C24H16N4O8
  12. Crystal structure of catena-(bis(μ2-1, 2-bis(imidazole-1-ylmethyl)benzene-κN:N′)-dichlororido-nickel(II)), C28H28Cl2N8Ni
  13. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-(4-methoxyphenyl)prop-2-en-1-one, C15H16N2O3
  14. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-phenylprop-2-en-1-one, C14H14N2O2
  15. Crystal structure of (E)-2-(4-hydroxy-3-methoxybenzylidene)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H18O4
  16. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-(4-ethoxyphenyl)-3-hydroxyprop-2-en-1-one, C16H18N2O3
  17. Crystal structure of (Z)-1-(1,5-dimethyl-1H-pyrazol-3-yl)-3-hydroxy-3-(p-toly)prop-2-en-1-one, C15H16N2O2
  18. Crystal structure of 1-acetyl-3-(3-chlorophenyl)-5-(4-isopropylphenyl)-4,5-dihydro-(1H)-pyrazole, C20H21ClN2O
  19. The crystal structure of 1-methyl-2,4-dinitro-5-iodoimidazole, C4H3IN4O4
  20. The crystal structure of 4-chloro-3,5-dinitroaniline, C6H4ClN3O4
  21. Crystal structure of N,N-dimethyl-N′-(2-methyl-4-oxo-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-3(4H)-yl)formimidamide, C14H18N4OS
  22. Crystal structure of tetrakis(μ2-acetato-κ2O:O′)-bis[μ3-4-chloro-2,6-bis((methylimino)methyl)phenolato-κ2N,O:O,N′]-(μ4-oxido)tetracopper(II), C28H32Cl2Cu4N4O11
  23. Crystal structure of catena-poly[diaqua-bis(μ2-ethane-1,2-diyl-bis(pyridine-3-carboxylate-κ2N:N′))copper(II)] dinitrate, C28H28CuN6O16
  24. Synthesis and crystal structure of catena-poly[(μ2-nicotinato-κ2O,O′: κ1N)-(nitrato-κ1O)-(bis(2-benzimidazol-ylmethyl)amine-κ3N,N′,N′′)lead(II)], C22H18N7O5Pb
  25. The twinned crystal structure of (4SR)-7-benzyl-2,4,8,8-tetramethyl-7,8-dihydroimidazo[5,1-c][1,2,4]triazine-3,6(2H,4H)-dione, C16H20N4O2
  26. Crystal structure of (Z)-3-hydroxy-3-(4-methoxyphenyl)-1-(pyridin-2-yl)prop-2-en-1-one, C15H13NO3
  27. Crystal structure of 2-amino-4-(2,3-dichlorophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H12Cl2N2O2
  28. Crystal structure of catena-poly[(μ2-butane-1,4-diyl-bis(pyridine-3-carboxylato-κN))silver(I)] tetrafluoroborate, C16H16AgN2O4BF4
  29. Crystal structure of poly[diaqua-(1,10-phenanthroline-κ2N,N′)-(μ2-2,5-dihydroxytere-phthalato)-bis(μ4-2,5-dihydroxyterephthalato)dicerium(III)], C24H16CeN2O10
  30. Crystal structure of 5,7,4′-trihydroxy-3,8,3′-trymethoxyflavone, C18H16O8
  31. Crystal structure of N-(3,4-dichlorobenzylidene)-4-methylaniline, C14H11Cl2N
  32. Crystal structure of 4-(3-Methoxy-phenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester, C22H27NO4
  33. Crystal structure of 2-amino-4-(3-fluorophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C16H13FN2O2
  34. Crystal structure of 1,1,(3,4-dihydroxythieno[2,3-b] thiophene-2,5-diyl)bis(2-bromoethanone), C10H6Br2O4S2
  35. The crystal structure of N,N′-(4,4′-oxydibenzyl)-bisisonicotinamide 3.5 hydrate, C24H24N4O6
  36. Crystal structure of catena-poly[hexakis(μ2-chlorido)-hexakis(4-(1H-pyrazol-5-yl)pyridine-κN)tricadmium(II)], Cd3C48H42Cl6N18
  37. Crystal structure of 2-(4-(dimethylamino)phenyl)-1,3-dimethyl-1H-perimidin-3-ium iodide, C21H22I1N3
  38. Crystal structure of 4-(1,3-dimethyl-2,3-dihydro-1H-perimidin-2-yl)benzonitrile, C20H17N3
  39. Crystal structure of tetrakis(μ2-acetato-κ2O:O′)-bis(2,2′-sulfonyldipyrazine-κ1N)dicopper(II), C24H24Cu2N8O12S2
  40. Crystal structure of 1-(4-chlorophenyl)-6,8-diphenyl-1H-pyrazolo[4,3-c]quinoline, C28H18ClN3
  41. Crystal structure of methyl 3-((1-(2-(methoxycarbonyl)benzyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-naphthoate, C24H21N3O5
  42. Crystal structure of (tris(2-pyridylmethyl)amine-κ4N,N′,N′′,N′′′′)-chloranilato-κO,O′-zinc(II) – methanol (1/1), C25H22Cl2N4O5Zn
  43. Crystal structure of 1,1-dimethyl-3-(4-methoxyphenyl)urea, C10H14N2O2
  44. Crystal structure of 4a-Hydroxy-9-(2-nitro-phenyl)-3,4,4a,5,6,7,9,9a-octahydro-2H-xanthene-1,8-dione, C19H19NO6
  45. Crystal structure of chlorido-(η6–1-isopropyl-4-methyl benzene)-(1-(pyridin-2-yl)-N-(p-tolyl)methanimine-κ2N,N′)ruthenium(II) hexafluorophosphate(V), C23H26ClF6N2PRu
  46. Crystal structure of phenyl(2-phenyl-2,3-dihydro-1H-perimidin-2-yl)methanone, C24H18N2O
  47. Crystal structure of (E)-3-methyl-4-((3-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1-phenyl-1H-pyrazol-5(4H)-one, C29H23N7O
  48. Crystal structure of 2-(4-(2-butyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)piperazin-1-yl)-2-oxoethyldiethylcarbamodithioate, C27H34N4O3S2
  49. Crystal structure of poly-[diaqua-bis(μ-4,4′-bipyridine-κ2N:N′)cobalt(II)] bis(4-chlorobenzenesulfonate) – 4,4′-bipyridine – water (1/1/2), C42H40Cl2CoN6O10S2
  50. Crystal structure of (η6-benzene)-(N-(2,6-dimethylphenyl)-1-(pyridin-2-yl)methanimine-κ2N,N′)ruthenium(II) perchlorate monohydrate, C20H20Cl2N2O5Ru
  51. Crystal structure of 4,10,16,22-tetrahydroxy-6,12,18,24-tetramethoxy-2,8,14,20-tetraethylphenylresorcin[4]arene – ethyl acetate (1/1), C68H72O10
  52. Crystal structure of chlorido-(N-(2,5-dichlorophenyl)-1-(pyridin-2-yl)methanimine-κ2N,N′)(η6-1-isopropyl-4-methyl benzene) ruthenium (II) tetrafluoroborate, C22H22Cl3N2BF4Ru
  53. Crystal structure of 3-(5-methyl-1-p-tolyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde, a rare Z′ = 3 structure, C20H17N5O
  54. Crystal structure of 5-(5-(4-chlorophenyl)-1-phenyl-1H-pyrazol-3-yl)-N-phenyl-1,3,4-thiadiazol-2-amine, C23H16ClN5S
  55. Crystal structure of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one-N,N-dimethylformamide (1/1), C18H17NO5
  56. Crystal structure of halogen-bonded 2-chloro-1,10-phenanthroline—1,4-diiodotetrafluorobenzene (2/1), C30H14Cl2F4I2N4
  57. Crystal structure of 1-(4,4-dimethyl-2,6-dithioxo-1,3,5-triazinan-1-yl)-3-(diethylaminocarbonyl)thiourea, C11H20N6OS3
  58. Crystal structure of methyl 1-(4-fluorobenzyl)-3-phenyl-1H-pyrazole-5-carboxylate, C18H15FN2O2
  59. Crystal structure of 1,1-dimethyl-3-(4-methylphenyl)urea, C10H14N2O
  60. Crystal structure of yttrium gallium antimonide, Y5Ga1.24Sb2.77
  61. Crystal structure of 2-(bis(4-methoxyphenyl)amino)-2-oxoacetic acid, C16H15NO5
Downloaded on 25.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0194/html?srsltid=AfmBOopxITW_oEEgNd0SFSYHWDiSqB8sxuT1ZaDFClFRAKmVzhzkMi0k
Scroll to top button